Immunovant enters $36M manufacturing deal with Samsung Biologics for batoclimab

Immunovant, Inc.

Minimum purchase commitment estimated at $36M; PSA runs through Dec 31, 2029.
Immunovant can terminate if it stops all batoclimab development by Jan 2024, paying non-cancellable fees.
Samsung will manufacture batoclimab drug substance for commercial sale, including process performance qualification batches.
Agreement builds on Master Services Agreement dated April 30, 2021.
Either party may terminate for material breach, insolvency, or force majeure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.